Synpromics Raises £5.2M of New Investment

Synpromics Raises £5.2M of New Investment
19.04.2017 08:30 am

Synpromics Raises £5.2M of New Investment

Investment Management

Synpromics Ltd, the leading synthetic promoter and gene control company, is delighted to announce that it has completed a financing round of £5.2M. Participants included existing investors Calculus Capital, the Scottish Investment Bank, the investment arm of Scottish Enterprise and private shareholders.

Synpromics has grown rapidly over the past two years as it expanded its portfolio of international customers. These include leading gene therapy companies and multinational technology corporations, most recently GE Healthcare.

The majority of the new investment will be used to further develop and exemplify Synpromics proprietary PromPT™ synthetic promoter design platform. PromPT™ enables the design of unique synthetic promoters which give precise control of gene function in many areas of gene medicine including gene therapy, cell therapy and gene editing. The Company is also preparing to move into a larger, new purpose built, facility.

David Venables, CEO of Synpromics, commented “Since our last fundraising round 18 months ago the business has grown rapidly as we’ve signed more commercial partnerships with companies in the US and Europe. We see an exciting opportunity to fund further rapid expansion of our business, supported by our innovative science and novel capabilities.”

Alexandra Lindsay, Investment Director at Calculus Capital, added “We have been delighted with the progress which Synpromics has made since we made our first investment some 18 months ago. They have a very strong team and the technology has been clearly validated through partnerships with some of the world’s leading gene medicine companies.”

Kerry Sharp, Head of the Scottish Investment Bank, said “Having supported Synpromics from an early stage it is great to see the progress that has been achieved to develop and grow the business in the highly dynamic synthetic biology industry. We look forward to continuing to work with the company, both from an investment perspective and through our account management support, to deliver its long term growth ambition.”

Related News

SimCorp launches new machine learning initiative with start-up, Alkymi

SimCorp targets institutional investment challenges with new machine learning initiative, in partnership with Alkymi.

Read more »

Washington Trust Bank Expands Partnership to Baker Hill NextGen

Baker Hill, the leading financial technology provider in delivering solutions for common loan origination, risk and relationship management, CECL, and smart data analytics,... Read more »

Digital proxy voting to bring greater transparency, efficiency to Australian AGMs in 2020

Digital proxy voting by institutional investors is expected to become a bigger focus at Annual General Meetings in 2020 after the successful deployment in Australia of Citi’s... Read more »

FNZ has secured investment from Temasek

FNZ, the global platform-as-a-service provider, has secured an investment from Temasek, a global investment company headquartered in Singapore.

FNZ, which specialises in... Read more »

Investors aged 28-37 years invest in long-term loans most often

Analysts of the P2P platform Robo.cash have studied the profile of its users investing in long-term loans... Read more »

Finastra strengthens its position in Israel with new office opening

Finastra is investing further in Israel with a new office in Kfar Saba, just outside Tel Aviv. The office, which is home... Read more »

Magazine
ALL
Free Newsletter Sign-up
+44 (0) 208 819 32 53 +44 (0) 173 261 71 47
Download Our Mobile App
Financial It Youtube channel